January 7, 2021 11:21 AM ESTUpdated January 8, 03:34 PM
News Briefing

News brief­ing: Pfiz­er kick­starts PhI­II tri­al for DMD gene ther­a­py, out­rac­ing Sarep­ta; Teva's re­for­mu­lat­ed schiz­o­phre­nia shot touts win in late-stage study

Kyle Blankenship

Max Gelman

Senior Editor

Conner Mitchell

In the race to bring the first gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy in­to a Phase III tri­al, Pfiz­er has come out on top over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times